Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

INTRODUCTION: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer death in China. Four epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors – afatinib, erlotinib, icotinib, and gefitinib – are available for first-line treatment of NSCLC in China; however, there a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Wu, Yi-Long, Xu, Chong-Rui, Hu, Cheng-Ping, Feng, Jifeng, Lu, Shun, Huang, Yunchao, Li, Wei, Hou, Mei, Shi, Jian Hua, Märten, Angela, Fan, Jean, Peil, Barbara, Zhou, Caicun
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2018
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6280988/
https://ncbi.nlm.nih.gov/pubmed/30584317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S160358
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky